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Particle accelerators were initially developed to address specific scientific research goals, yet they were 
used for practical applications, particularly medical applications, within a few years of their invention. 
The cyclotron's potential for producing beams for cancer therapy and medical radioisotope production 
was realized with the early Lawrence cyclotrons and has continued to grow with more technically 
advanced successors - synchrocyclotrons, sector-focused cyclotrons and superconducting cyclotrons. 
While a variety of other accelerator technologies was developed to achieve today’s high energy particles, 
this contribution will chronicle the development of one type of accelerator, the cyclotron and its medical 
applications. These medical and industrial applications eventually led to the commercial manufacture of 
both small and large cyclotrons and facilities specifically designed for applications other than scientific 
research.  
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1. Introduction 
The discovery by Rutherford in 1919 that nuclear 
disintegration could be caused by bombarding nitrogen 
with alpha particles from a naturally occurring 
radioactive substance precipitated an intense effort to 
produce ever more energetic nuclear particles to probe 
and understand matter. The result has been an exciting 
period of development of a variety of machines (particle 
accelerators) to produce charged particles of 
increasingly high energies to probe the nucleus. This 
development, which started with simple electrostatic 
linear accelerators in 1924 and the Lawrence cyclotron 
in the 1930’s, continues today with the commissioning 
of the LHC at CERN [1]. Particle energies have 
increased over the last 80 years to nearly 107 times that 
available from naturally decaying elements, and have 
allowed a rich, if not yet complete, understanding of the 
makeup of matter and the Universe.  
     Many different methods for producing high energy 
nuclear particles were proposed and developed since 
Rutherford’s call for “a copious supply” of more 
energetic particles in 1919. These methods are discussed 
in previous review articles in Vol. 1 of this journal [2].  
This contribution will focus on one method of 
acceleration, the cyclotron, particularly in relation to the 
precipitant development of the medical applications 
spawned by it—applications which continue to expand 
today.                                                                                       
     From its inception in 1930 by E.O. Lawrence [3] 
through its many design variations to increased particle 
energy and intensity for research, the cyclotron has been 
used for a variety of biological, medical and industrial 
applications. Soon after the first experimental 
demonstration of the cyclotron resonance principle by 
Earnest Lawrence and Stanley Livingston [4] [5], new 
radioisotopes produced by high energy particles were 
discovered and used for the study of both biological 
processes and chemical reactions.  Lawrence developed 
the cyclotron for nuclear physics research, yet he was 
very much aware of its possible applications in 
medicine. An interesting and comprehensive historical 
review of the development and growth of medical 
applications for cyclotron produced beams and radio- 
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Fig. 1. Donald Cooksey and Ernest Lawrence (right) at the completed 
60-inch cyclotron in the Crocker Laboratory. 
 
isotopes initiated at Berkeley by E.O. Lawrence and his 
colleagues can be found in [6].  
      The earliest medical applications of cyclotron 
beams began at the University of California, Berkeley 
when Lawrence brought his brother John to join 
Lawrence’s group in 1935 [7]. John Hundale Lawrence, 
a physicist with an M.D. from the Harvard Medical 
School (1930), quickly demonstrated the worth of 
cyclotron produced radioisotopes in disease research 
[8].  He became the Director of the Division of Medical 
Physics at the University of California at Berkeley. In 
1936 he opened the Donner Laboratory to treat leukemia 
and polycythemia patients with radioactive phosphorus 
(32P) [9]. These were the first therapeutic applications of 
artificially produced radioisotopes on human patients. 
By 1938, the Berkeley 27-inch (later upgraded to 37-
inch) cyclotron had produced 14C, 24Na, 32P, 59Fe and 
131I radioisotopes, among many others that were used 
for medical research [6]. 
      Lawrence believed in the promise of accelerator-
produced radioisotopes as a possible weapon against 
disease and heralded these biomedical applications to 
appeal to local philanthropists to fund his accelerator 
development programs. Philanthropies at the time 
donated more money to medicine, public health, and 
biology than to physics. His appeals attracted funding 
for the 200-ton multi-use Crocker 60-inch (magnet pole) 
diameter cyclotron in 1938, which was commissioned in 
1939, ostensibly, as a “medical” cyclotron.  One might 
consider the Crocker machine to be the first cyclotron 
built specifically for medical research and applications. 
A photo of the completed cyclotron is shown in Fig. 1.    
      John Lawrence and Cornelius Tobias, another 
student of Ernest Lawrence, used this cyclotron to 
research one of the earliest biomedical uses of 
radioactive isotopes. They used radioactive nitrogen, 
   
 
Fig. 2. E. O Lawrence (seated), the inventor of the cyclotron, and his 
brother, J. H. Lawrence, the “Father of Nuclear Medicine”, at the 
console of the Crocker 60-inch cyclotron.   
 
argon, krypton, and xenon gases to provide diagnostic 
information about the functioning of specific human 
organs. Their research discovered the nature of the 
decompression sickness known as the “the bends,” 
experienced by many military aviators when flying at 
high altitudes without pressurized suits [10]. A photo of 
the Lawrence brothers at the console of this cyclotron is 
shown in Fig. 2. 
      In other activities, Dr. John Lawrence and Dr. 
Robert Stone were the first to use hadron therapy to 
treat cancer using the Crocker 60” cyclotron. They 
began clinical trials treating cancer with neutrons in 
1938, just six years after the discovery of the neutron by 
Chadwick in 1932. Neutron radiation damage is done 
primarily by nuclear interactions, interactions that are 
now known to  have a high linear-energy-transfer (high 
LET).  With high LET radiation such as neutron 
radiation, the chance for a damaged tumor cell to repair 
itself is very small [11].  A photo of a patient being 
prepared for a neutron treatment is shown in Fig.3. This 
initial work was terminated because the cyclotron was 
needed for the war effort during World War II. 
However, after the war, a renewed interest in neutron 
therapy precipitated clinical trials at several facilities 
around the world in the 1970’s.  Except for the early 
trials at Berkeley, most of the later trials were conducted 
using accelerators other than cyclotrons. By the 1980’s, 
neutron therapy was no longer used for routine cancer 
treatment.   
       Robert Wilson, yet another graduate student of 
Lawrence, realizing the advantages of the hadron Bragg 
peak, proposed the use of high-energy protons and other 
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Fig. 3.  John Lawrence and Robert Stone setting and preparing a 
patient for neutron irradiation at the 60” Crocker cyclotron in 1938. 
 
charged ions to treat deep-seated tumors in the human 
body [12]. The basic physics that makes hadron therapy 
so attractive is the manner in which high energy ions 
lose energy while passing through matter. Energetic 
ionizing (charged) particles loose energy slowly through 
atomic interactions as they penetrate matter until near 
the end of their range, where they give up the last 85% 
of their energy. This energy loss profile is illustrated in 
Fig. 4 for a 160 MeV proton beam. The large energy 
loss peak at the endpoint (blue curve) at 15 cm into the 
body is called the Pristine Bragg Peak. Protons are 
known today as low LET radiation. However, the depth 
that an energetic proton will penetrate into the human 
body varies predictably with energy, such that most of 
the proton energy can be delivered precisely in a tumor 
at any depth by selecting the appropriate energy. Beams 
of lower energies and intensities can be directed at the 
tumor so as to cover the whole depth of the tumor. This 
is shown in Fig. 4 for a 9 cm Spread Out Bragg Peak or 
SOBP (Red Curve). The radiation damage to the body 
during entry is significantly less than in the tumor. Since 
the beam stops in the tumor, very little damage is done 
behind it.  An energy deposition profile for a 10 MeV 
photon (grey curve) is also shown on the same scale in 
Fig. 4 for comparison—illustrating higher entry and exit 
doses to the patient together with a smaller energy 
deposition in the target (tumor) area.  The energy loss 
profile for a neutron is similar in shape to that of a 
photon, hence these particles damage both cancerous 
and healthy tissue. The proton, though a low LET 
particle, has the advantage that it can concentrate its 
energy in the tumor. 
      Wilson’s proposal led to the routine use of high 
energy ion beams for the direct treatment of localized 
(cancerous) tumors within the human body. Today there 
Fig. 4. Energy loss profiles for a 160 MeV proton beam compared 
with a 10 MeV Photon. A 160 MeV proton Pristine Bragg peak (Blue 
curve) and a combined energy 9 mm Spread Out Bragg peak (SOBP) 
made of a series of lower energy proton beams (Red Curve) are 
shown. 
       
are over 30 operating Ion Beam Therapy (IBT) facilities 
around the world, many of them designed and built by 
commercial vendors, with several more planned or 
under construction. Over 60% of these facilities use one 
commercial cyclotron design as the source of energetic 
ions required for the treatment [13].       
      Through these and other pioneering work, John 
Lawrence became known as the “Father of Nuclear 
Medicine and the Donner laboratory is recognized as its 
birthplace” [14].  The cyclotron development activities 
at the Berkeley Radiation Laboratory became the 
crucible for the growth of nuclear medicine and hadron 
therapy as an indispensable part of modern health care. 
Accelerator produced radioisotopes are now routinely 
used for imaging diagnostics or to treat diseases. 
Human organs can be readily imaged, and disorders in 
their function revealed. “It is estimated that 15 to 20 
million nuclear medicine imaging and therapeutic 
procedures are performed every year around the world, 
and demand for radioisotopes is increasing rapidly. In 
developed countries (about a quarter of world 
population) the frequency of diagnostic nuclear 
medicine procedures performed is approximately two 
per 100 persons per year, and the frequency of therapy 
with radioisotopes is about one tenth of this” [6].  
       In the sections that follow, the development of the 
cyclotron, from the classical design invented in 1930 by 
Lawrence to the relativistic superconducting machines 
of today, will be briefly reviewed; and, the medical 
applications that each new capability inspired will be 
presented. While virtually all the advances in cyclotron 
design and performance were accomplished in the 
pursuit of scientific research, there was a persistent 
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demand for access to them for applications in medicine 
and industry. The rapid advances in cyclotron 
performance quickly made earlier designs obsolete 
for research, and many of these were given over to 
medical research and applications work. This growing 
demand eventually (~1970) made the commercial 
manufacture of cyclotrons dedicated to these 
applications viable. These commercially developed and 
manufactured machines and their medical applications 
will be given special attention.  
2. A Brief Review of Cyclotron Development 
2.1. The Classical Cyclotron 
The classical cyclotron (also called “conventional” or 
“Lawrence” cyclotron) invented by Lawrence in 1930 
was quite simple in concept and construction. The 
underlying physics principles are that charged ions 
(protons, electrons, etc) are accelerated with electric 
fields and contained or focused by magnetic fields. 
Lawrence’s brilliant insight was that the orbit period of 
a particle of charge q, mass m and velocity v traveling in 
a circle in a uniform magnetic field B normal to the 
particle velocity is constant; only the radius R of the 
orbit increases with the particle momentum (mv) [15] 
[16]. 
                                  R = mv/qB                              (2.1) 
 
The particle orbit period t is given by; 
 
                              t = 2pm/qB                             (2.2) 
 
Hence, a constant frequency sinusoidal oscillating 
voltage on the accelerating cavities, called dees because 
of their shape, matching the cyclotron resonance 
condition (w = qB/m) accelerates the particles twice per 
revolution, causing them to increase their orbit radius as 
they gain energy. The repetitive dee gap crossing of the 
recirculating beam allows it to be accelerated to high 
energies with relatively low dee voltages, thus 
eliminating the need for the high voltages used on the 
competing technologies of the time, the Van de Graaff 
[17] and Cockcroft-Walton linear accelerators [18].        
      The ideal kinetic energy gain per revolution in a 
cyclotron for a synchronous particle of charge q is   
given by: 
                                      T = 4qVo                            (2.3) 
 
For a peak dee voltage Vo of ± 2 kV, a particle of charge 
q receives an 8 keV kinetic energy gain per revolution, 
i.e., each time it crosses the gap between the dees (every  
 
 
Fig. 5. A three dimensional exploded view of the major cyclotron 
electromagnetic components as invented by Ernest Lawrence in 1930. 
 
180o of rotation) it receives and energy gain of 4 keV.  
A proton traversing 300 orbits would gain a maximum 
of 2.4 MeV. A classic schematic showing the major 
electromagnetic components of a conventional 
cyclotron is shown in Fig. 5. 
 
2.1.1. Orbital Stability 
 
A critical design issue for all particle accelerators is the 
orbital stability of the circulating beam during 
acceleration. The particles must remain focused into 
small bunches in all three spatial dimensions and orbit 
oscillations about the magnet mid-plane and equilibrium 
orbit must be small enough to keep beams from getting 
lost on the magnet poles or dee structures. Electric and 
magnetic restoring forces must be built into the 
accelerator to keep the beam centered in the orbit. Also, 
the magnetic field must be constant to a high precision 
to maintain a constant orbit frequency that matches the 
constant RF electric field frequency throughout the 
many revolutions of the acceleration cycle.  This later 
condition, called “isochronism,” insures that the 
particles arrive at the acceleration gap when the RF 
voltage is near its peak value Vo . The two requirements 
of beam focusing and isochronism compete with one 
another in the classical cyclotron and ultimately limit 
the maximum energy of this initial design. 
2.1.2. Focusing 
      Beam focusing and orbit stability in a cyclotron 
requires a small restoring force to push a divergent 
circulating beam back into the mid-plane equilibrium 
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orbit. The magnetic field of a classical cyclotron shown 
in Fig. 5 tends to bulge out and decrease slightly with 
radius because of leakage near the pole outer edges. The 
resulting magnetic field thus has a small radial 
component (Br) that applies weak axial and radial forces 
to the circulating beam. The slight field decrease with 
radius is too small to provide the necessary focusing 
forces to keep the beam in the machine throughout the 
acceleration cycle. Lawrence’s team added iron “shims” 
to the magnet pole tips to produce a more rapid field 
fall-off with radius to provide the required focusing 
forces. The shims, shown in Fig. 6, increase the pole 
gap from the center outward with radius to reduce the 
field in a controlled way.  The field decrease with radius 
for a classical cyclotron is; 
                               Br = - nBoz/R                            (2.4) 
where n is a constant defined as the “Field Index.”  The 
resulting radial and axial focusing forces are: 
                              Fr = - mw2 (1-n) r                                       (2.5) 
                              Fz = - mw2nz                              (2.6) 
For values of 0 < n < 1, these forces keep the beam 
focused and cause it to make small oscillations about 
the magnet mid-plane during acceleration. The orbit 
oscillation frequencies are called “Betatron Tunes” and 
are given by; 
       νr  = w(1-n)1/2/2p       (2.7) 
       νz  = w(n)1/2/2p        (2.8) 
where again w/2p is the particle orbit frequency [19].  
The resulting oscillation period of a deviant particle 
about the equilibrium orbit in both the axial and radial 
directions is smaller than the orbit frequency, the 
definition of a weak focusing accelerator. The 
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Fig. 6. A cross-sectional view of a cyclotron magnet pole gap showing 
the field shaping shims (blue) installed to provide a stable circulating 
beam during acceleration.  
mathematical formalism for the above equations can be 
found in reference [16]. 
 
2.1.3. Isochronism 
 
For a constant sinusoidal rf accelerating voltage ±Vo, a 
synchronous particle arriving at the dee gap at the 
maximum voltage receives a kinetic energy gain per 
revolution given in equation 2.3, as shown for three 
consecutive orbits (blue dots) in Fig. 7.  The only force 
maintaining the particle in synchronism with the 
accelerating voltage is the magnetic field, which must 
be maintained to a very high precision (~0.1%) for 
particles making hundreds of turns. Variation in the 
magnet gap or the magnet excitation current will cause 
the particle orbit period to deviate from the synchronous 
value. For a field constrained to decrease with radius as 
required for focusing, the particle orbit periods will be 
longer than the synchronous orbit, and will hence arrive 
at the dee gap at increasingly later times (red dots) 
relative to the rf period, causing the particles to become 
increasingly out of phase with the rf electric field. This 
is referred to as “Phase Slip,” i.e., the particles slowly 
slip out of phase with the rf accelerating voltage with 
each passing turn. Two things happen when this occurs. 
First, the accelerating voltage experienced by the 
particle is less than Vo, i.e; 
                                V = Vo Cosθ                            (2.9) 
where θ is the rf phase angle traversed during a single 
particle orbit. The resulting kinetic energy gain per turn 
would then be: 
                               T = 4qVoCosθ                         (2.10) 
The lower energy gain per turn causes the particles to 
make a larger number of orbits in the cyclotron to reach 
the maximum design energy.  In the worst-case 
scenario, the particles will eventually arrive late enough 
after many turns to receive no acceleration or even 
deceleration.  Second, an increase in the particle bunch 
spatial size and time width during acceleration, also 
shown in Fig. 7. Both effects cause beam intensity loss 
during the acceleration process.             
      Yet a third effect of acceleration in any cyclotron 
that causes the particles to lose synchronism with the 
fixed frequency rf electric field is that the particle mass 
m(t) increases with velocity according to Einstein’s 
theory of relativity.  As the particle velocity v(t) 
increases with time, the particle mass m(t) increases 
according to;  
                       m(t) = mo/(1 – β(t)2)1/2                   (2.10) 
where mo is the particle mass at rest, β(t) = v(t)/c and c 
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Fig. 7.  Sinusoidal RF accelerating voltage illustrating Isochronous 
acceleration (blue) and “phase slip” due to a decreasing magnetic field 
with radius (red) for three revolutions.   
       
is the speed of light. A 20 MeV proton’s mass is 2% 
higher than one at rest according to eq. (2.10). This 
mass increase further increases the orbit period (eq. 2.2) 
adding to the loss of synchronism. To compensate for 
the relativistic mass increase with energy, the field must 
increase with radius in proportion to the particle mass 
increase—exactly the opposite of what is required for 
focusing.  Using high dee voltages to reduce the number 
of turns required to achieve maximum energy can 
mitigate the competing requirements of relativity, 
focusing and isochronism. Even with this, the maximum 
proton energy capability of the classical cyclotron 
originally invented by Lawrence can be shown to be 
approximately 20 MeV. This situation lasted until about 
1958 for the classical cyclotron design. 
      In the years following the development of the first 
practical cyclotron (11”, 1.2 MeV p) in 1932, several 
larger cyclotrons were constructed at Berkeley and 
many machines were subsequently built around the 
United States and the world. At Berkeley, Lawrence 
built the 27” (3.6 MeV p, 1932), 37” (8 MeV d, 1937) 
and 60” Crocker (16 MeV d, 1939) cyclotrons and 
started the construction of the 184” cyclotron.  Designed 
for 340 MeV protons, this machine would not have 
worked as a classical cyclotron for the reasons just 
described, but was modified to operate as a 
synchrocyclotron. Lawrence’s graduate students and 
other scientists from Berkeley started the construction 
of many research cyclotrons at other institutions based 
on the classical Berkeley designs. By the late 1930’s, 
machines were built at Cornell (S. Livingston), 
Columbia, Indiana University (Franz Kurie and L. J. 
Laslett), Princeton, MIT (S. Livingston) Rochester, and 
Yale, just to name a few of the approximately 24 
cyclotrons operating or under construction at academic 
institutions around the United States by the mid 1940’s 
[20]. Cyclotrons were also built in Sweden (Stockholm, 
32”), Japan (Reiken, 26”) and Europe.  Some of these 
machines were used for medical and scientific studies 
well into the 1960’s. 
2.2. The Synchrocyclotron  
 
One obvious solution to the classical cyclotron energy 
limit is to reduce the frequency of the rf accelerating 
voltage with time in synchronism with the increase in 
the particle orbit period caused by the effects, primarily 
relativity, described above, i.e; 
                          wrf(t)  = qB/m(t)                          (2.11) 
This “frequency modulated” (fm) operation requires a 
single beam bunch to be accelerated with the phase of 
the accelerating particles shifted to be between 40o and 
60o after the voltage peak as shown in Fig. 8. The 
synchronous accelerating voltage Vs is then less than 
Vo. When a particle is out of phase with wrf(t), i.e, has 
an orbit period either smaller (θmin) or larger (θmax) than 
the synchronous value (θs), it receives a energy gain  
less or greater than 4qVoCosθs. This causes the particles 
orbit period to move back toward the synchronous value 
over several orbits, acting like a feedback loop. 
Consequently, the particle orbit period will oscillate 
about the synchronous value during the acceleration 
cycle, a process called Phase Stable Acceleration. The 
phase angle range (θmin - θmax) of the particle motion 
is referred to as an “RF Bucket.” The principle of 
“Phase Stability” was postulated simultaneously by 
Veksler [21] and McMillan [22], and is also the 
fundamental principle for acceleration in a synchrotron. 
Phase stable acceleration also allows the particles to 
accelerate through small magnetic field anomalies in the 
cyclotron caused by pole tip machining errors and poor 
magnet excitation current regulation. One drawback of 
the synchrocyclotron is that once a beam bunch is 
captured and accelerating, the next bunch cannot be 
accelerated until the first is accelerated to full energy 
and the rf frequency reset to the injection value. The  
 
 
Fig. 8. RF acceleration cycle illustrating the principle of Phase Stable 
Acceleration in a synchrocyclotron. The area between θmin and θmax 
is the “RF Bucket”.  
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Fig. 9. The Berkeley 184” synchrocyclotron, 1946. 
 
resulting extracted beam has a pulse period several 
thousand times the rf accelerating frequency, compared 
to the classical cyclotron pulse period of twice the 
accelerating RF frequency—significantly reducing the 
average extracted beam intensity.  
     The principle of phase stable acceleration was first 
demonstrated when the 37” Berkeley cyclotron was 
converted to a synchrocyclotron in 1946 [23]. The 184” 
cyclotron at Berkeley, shown in Fig. 9, was then quickly 
redesigned to operate as a synchrocyclotron capable of 
accelerating protons to 350 MeV. Following these 
successes at Berkeley, 14 large synchrocyclotrons were 
constructed around the world that produced proton 
beams of up to 1 GeV (Gatchina) in energy [24].  
 
2.2.1. Early Proton Therapy Medical Developments 
 
     The higher beam energies (>100 MeV Protons) of 
the synchrocyclotron gave medical researchers the 
opportunity to study and test proton beam therapy as 
originally proposed by Robert Wilson in 1946 [12]. 
John Lawrence was the first to treat cancer patients with 
high energy protons in 1954 using the Berkeley 184” 
synchrocyclotron by irradiating the pituitaries of 30 
patients with metastatic breast cancer [25].         
      Another of the early synchrocyclotrons, the Harvard 
synchrocyclotron commissioned in 1949 (160 MeV p), 
shown in Fig. 10, would go on to become a dedicated 
proton source for a pioneering program of Ion Beam 
Radiation Therapy for cancer from the 1960’s until its 
decommissioning in 2002.  Robert Wilson established 
many of the design parameters for this machine while 
he was an associate professor at Harvard, during which 
he published the famous paper proposing the use of 
high-energy protons for the treatment of deep seated 
tumors in the human body [12]. After a distinguished  
 
 
Fig. 10.  Photo of the Harvard 160 MeV synchrocyclotron just prior to 
its commissioning on June 15, 1949, with Professors Norman Ramsey 
(R, Cyclotron laboratory Director) and Lee Davenport (Associate 
Director).  This machine was shut down on June 20, 2002. 
 
career in nuclear and medical research, the Harvard 
accelerator was used to begin a study of the treatment of 
various neurological lesions with high-energy protons in 
the 1960’s in collaboration with the Massachusetts 
General Hospital (MGH) neurosurgery department. This 
collaboration resulted in the development of several 
important beam manipulation techniques (double 
scattering, range modulation), treatment protocols and 
patient immobilization techniques for proton 
radiotherapy that are still in routine use today [26].  
9,115 patients were treated using the Harvard 
synchrocyclotron from 1961 until its decommissioning 
in 2002.   
     Another of these early synchrocyclotrons performed 
preliminary studies of Proton Beam therapy from 1957 
to 1968. On December 9, 1951, a synchrocyclotron with 
a radius of 90” and a maximum energy of 200 MeV for 
protons was commissioned at the Gustaf Werner 
Institute (GWI) in Uppsala, Sweden with Ernest 
Lawrence in attendance. This machine was used for 
radio therapeutic research and clinical tests with 185 
MeV proton beams from 1957 to 1968. These are but a 
few examples of how early physics driven accelerators 
were used for medical research and applications, a trend 
that still continues to this day.  
2.3. The Thomas (Isochronous) Cyclotron 
     The major disadvantage of the synchrocyclotron, low 
average intensity pulsed beams, was overcome by the 
development a third type of cyclotron known as the 
isochronous cyclotron which is capable of accelerating a 
continuous stream of particle bunches at a constant orbit 
frequency to high energies. The approach to addressing 
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the relativistic mass increase of eq. (2.10) is to allow the 
field to increase radially at the same rate as the 
relativistic mass increases during acceleration.  The 
radial field variation of the axial component of the 
magnetic field must be; 
           
! 
B
z
= B
0
/ 1" (Z
A
)
2
(r
a
)
2[ ]
1/ 2
                 (2.12)  
 
where
! 
a = E
0
/ecB
0
.  With this radial field variation, 
the cyclotron frequency is constant and independent of 
energy. 
 
2.3.1. The Radial Ridge Cyclotron 
 
      The high energy isochronous cyclotron was not 
considered in the early days of cyclotrons because the 
increasing field violated the conditions necessary for 
axial stability (0 < n < 1) of the classical and 
synchrocyclotrons discussed earlier.  A method to 
overcome the weak focusing properties of the required 
radially increasing field was proposed in 1938 by 
Llewellyn Thomas [27]. Thomas proposed to use an 
azimuthally varying magnetic field to provide edge 
focusing for particles entering and exiting the high and 
low field regions of the magnet. This was accomplished 
by dividing the cyclotron magnet pole faces into regions 
of high fields, called “Hills” (H), and low fields, called  
 
 
 
Fig. 11.   Schematic of a four sector radial ridge cyclotron magnet 
showing the non-circular obits, the Thomas angle and the regions of 
high (H) and low (V) fields. 
“Valleys” (V), such that the average radial field of the 
cyclotron increases with the energy according to eq. 
(2.13) to maintain a constant orbit period. The simplest 
example of this is the four sector radial ridge cyclotron 
magnet pole face depicted schematically in Figs. 11 and 
12. 
      The azimuthally varying magnetic field makes the 
protons travel in non-circular orbits causing them to 
pass through the interface between the high and low 
fields at an angle k, referred to as the ‘Thomas’ angle.  
The radial components of the fields at the interface can 
be made strong enough to produce adequate radial and 
axial focusing forces to maintain beam stability 
throughout the acceleration cycle. These forces are 
proportional to the Thomas angle k and the ratio of the 
high and low field values, which must be calculated 
during the design of the accelerator. An ion traversing a 
pole gap with an axial variation in pole height sees a net 
axial focusing force back towards the cyclotron median 
plane, as shown in Fig. 10.  A photo of a commercially 
available isochronous 24 MeV proton cyclotron using 
radial ridge pole tips is shown in Fig. 13 [28].  
      While the benefits of fixed frequency and CW 
(continuous dc beam) operation were clear, it took a 
while for this ‘Thomas’ cyclotron to be adopted. The 
first operational isochronous cyclotron was a three 
sector radial ridge electron machine constructed and 
operated at Berkeley during the 1950s.  This major 
development was deemed classified and therefore not 
made public until 1956 [29]. The first isochronous 
proton cyclotron, a 3 radial sector machine with a pole  
 
 
 
Fig. 12. An isometric view of the pole tip geometry for a four-sector 
radial pole tip gap variation needed for a Thomas Cyclotron. The 
“Valley” and “Hill” pole tip gaps gV  and gH are shown. 
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Fig. 13. Photo of the lower pole tip of an Advanced Cyclotron 
Systems TR 24 radial ridge cyclotron. This cyclotron delivers up to 1 
amp of 15 to 24 MeV protons to produce PET or SPECT Isotope. 
 
diameter of 86 inches, was built at DELFT in 1958. This 
machine accelerated protons to 12.7 MeV [30].  Another 
demonstration of such focusing was the Thomas 
shimmed classical cyclotron at Los Alamos National 
Laboratory [31]. 
     The slow adoption of Thomas’s 1938 proposal seems 
to be due both to the fact that the orbit dynamics of this 
machine needed to be absorbed by the cyclotron 
builders, and also that the existing cyclotrons of the 
1930-40s were simply adequate for the nuclear research 
in progress. The priorities of WWII once again had a 
role in the slow development of this concept.  
Eventually the demand for higher energies and 
intensities for nuclear science forced the development of 
the isochronous cyclotron.  By 1959, there were two 
isochronous cyclotrons in operation and another 13 in 
various stages of design and assembly.   
      The pole field variation required to provide the 
Thomas focusing may be done with a sine wave or 
square wave pole gap variation, and with radial or spiral 
ridge pole shapes. From the beginning, a distinguishing 
feature of isochronous cyclotrons was that a quantitative 
beam dynamics simulation was required to verify the 
field design, and indeed one of the first uses of the new 
digital computers in the 1950s was for the design of an 
isochronous cyclotron.  The complete theoretical basis 
of the isochronous cyclotron, in which it is seen that 
Thomas focusing is an example of the general principle 
of Alternating Gradient Focusing, is shared with another 
accelerator type, the Fixed Field Alternating Gradient 
accelerator (FFAG), and was developed principally by 
members of the MURA Group in the mid-1950s led by 
Symon. [32]. From the late 1950s onward most new 
cyclotron projects were based upon this isochronous 
cyclotron type.   
 
2.3.2. The Spiral Ridge Cyclotron 
 
     The energy capability of the radial ridge design is 
limited to about 45 MeV by the small Thomas angle that 
can be achieved, which limits the strength of the axial 
focusing forces that can be obtained. This constraint 
was removed by the introduction of spiral, rather than 
radial ridge pole tip sectors. The spiral angle magnet 
pole sectors caused the circulating particles to cross the 
pole edges at an angle greater than the Thomas angle, 
producing a stronger axial focusing force. The spiral 
pole tip shape can be adjusted during the design process 
to select the strength of the focusing required for orbit 
stability. This process could not be done empirically, 
but required the use of digital computers, which became 
available to scientists in the late 1950s. The radial and 
spiral ridge cyclotrons belong to a cyclotron group 
referred to as isochronous, azimuthally varying field, 
and sector-focused cyclotrons. One of the largest spiral 
ridge cyclotrons, TRIUMF, was made in Vancouver, 
B.C. This accelerator, a 6 sector cyclotron shown in Fig. 
14, accelerated H- ions to 520 MeV and is physically  
the largest cyclotron ever built (pole diameter of 17.17 
m) because the maximum field was limited to 6 kG to 
prevent magnetic striping of the H- ions during the 
acceleration process [33].           
      The development of the sector-focused cyclotron 
required sophisticated machining and fabrication 
techniques, and was initially available only for scientific 
research. However, the efficiency and compactness of  
 
 
 
Fig. 14. TRIUMF spiral ridge cyclotron pole magnets shown during 
construction.  
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Fig. 15.  A four sector isochronous cyclotron magnet pole tips with 
spiral edges   
 
the design made these cyclotrons ideal for the 
production of medical isotopes for SPECT and PET. 
Today, with the omnipresence of accelerator design 
computer codes, the sector-focused cyclotron has 
become an immensely practical high energy, efficient 
and relatively low cost machine that has made the 
applications of high energy particle beams a common 
commercial commodity used for the production of a 
 large number of medical imaging, diagnostic and 
therapeutic applications.  One example of a commercial 
cyclotron employing the spiral ridge pole design is the 
General Electric 14 MeV proton “PETrace” isotope 
production cyclotron [34], shown in Fig. 15. These 
commercial machines will be discussed later in Section 
3. 
2.3.3. Separated-Sector Ring Cyclotron  
 
       The separated sector cyclotron is the logical 
extension of the sector-focused design where the valleys 
are eliminated and the cyclotron is constructed from 
individual magnets spaced in the form of a ring. Willax 
proposed this design in the 1960s [35].  The first two 
machines of this design were constructed at PSI in 
Zurich, Switzerland (590 MeV Protons) [36] and at 
Indiana University (IUCF) in Bloomington, Indiana 
(200 MeV Protons) in the 1970s [37].  Each cyclotron 
was designed for a different particle and energy range, 
have different numbers of dipole magnets (8, 4 
respectively) and employ different pole shape designs 
(spiral and radial pole edges), as shown in Figs. 16 and 
17, which illustrates the flexibility of the ring cyclotron 
design. The PSI and IUCF cyclotrons, the first of their 
type, became operational for the first time in 1975. 
      The separated sector cyclotron has several practical 
advantages over the sector-focused designs. The RF 
accelerating dee structures can be removed from the 
 
 
Fig. 16. PSI K600 8 sector isochronous cyclotron. Four accelerating 
structures located between the spiral ridge magnets that produce an 
energy gain of 2.9 MeV per revolution. This machine holds the world 
record for beam intensity extracted from a cyclotron (2 mA protons). 
 
magnet gap and relocated between the individual 
magnets, making their design more efficient and 
powerful. Several high power accelerating dee 
structures can be located symmetrically between the 
magnets that accelerate the beam twice per dee passage, 
or twice the number of dee structures used, resulting in 
multi-MeV energy gains per revolution. Four 
accelerating structures located between the spiral edge 
magnet sectors, as seen in Fig. 15 for the PSI eight 
sector cyclotron, produce an energy gain of 2.9 MeV 
per revolution throughout the acceleration cycle. Beam 
extraction efficiencies  
 
 
 
Fig. 17. The Indiana University K220 four sector cyclotron is shown 
during construction. Two of the four gaps between the magnets 
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contained accelerator structures that give up to 0.8 MeV energy gain 
per turn. 
approaching 100% can be achieved. The beam injection 
and extraction devices can also be removed from the 
magnet gaps and placed in the spaces between the 
magnets.  With all this hardware removed from the 
magnets, the magnet gap can be reduced to no more 
than that required for beam orbit containment. Since the 
electrical power required to generate the resonant 
magnetic field increases as the square of the magnet 
gap, the magnet operating efficiency can be made very 
high. It also produces a sharper field edge between the 
high and low field regions of the ring,    providing 
increased axial focusing needed for the higher energy 
beams.        Another example of the versatility of the 
separated sector design is the IUCF cyclotron.  This 
accelerator was originally constructed as a variable 
energy (20 through 370 MeV) and multi-particle (p, d, 
3,4He, 6,7 Li) research machine. To achieve this wide 
range of particles and energy, the magnet pole faces 
were augmented with a set of 21 trim coils that could 
shape the magnetic field as a function of radius to match 
the relativistic requirements of each particle and energy 
selected. The field increase from injection to extraction 
required for 220 MeV protons was 25%, while the field 
could essentially be constant with radius for low energy 
helium and lithium beams. The trim coils required as 
much power to operate for high energy proton beams as 
the main magnets themselves. This facility is yet 
another example of a research cyclotron completing its 
scientific mission and then being dedicated to medical 
and industrial applications. The IUCF facility was 
converted into a Proton Therapy cancer treatment 
facility (MPRI) in the years between 2000 and 2006 and 
the cyclotron was reconfigured to operate as a 205 MeV 
fixed energy proton source [38]. This cancer treatment 
facility, which continues to operate today, will be 
discussed in more detail in Section 3. 
     The separated sector cyclotron is neither compact nor 
generally suited for practical medical applications 
because of its size and complexity. These high energy 
and intensity machines were designed for scientific 
research, and have higher performance capabilities than 
required for medical use.  Nevertheless, most of the 13 
large separated sector ring cyclotrons [24] devote some 
of their time to the development or application of 
hadron therapy. Indeed, places such as PSI, IUCF and 
NAC have helped pioneer some of the more advanced 
applications of hadron radiation therapy 
  
2.4. The Superconducting Cyclotron 
 
 In the late 1960s and early 1970s, large scale 
superconducting magnets, based upon NbTi conductors 
operating at liquid helium temperatures, began to appear 
in advanced scientific applications including bubble 
chamber magnets, fusion experiments and Magneto 
Hydro Dynamic (MHD) devices.  As the set of technical 
developments that made possible these new 
superconducting magnetic devices, which operate at 
fields as high as 3-4 Tesla, became more widely known, 
cyclotron designers began to consider their possible role 
in isochronous cyclotrons. One of the vexing problems 
of isochronous cyclotron design had been that at the 
practical limit of magnetic excitation levels of resistive 
copper windings, typically less than 2 Tesla, the iron in 
the cyclotron had a wide range of saturation 
magnetizations that could not be modeled with the tools 
available, and hence model magnets were needed to 
verify and optimize the orbit properties of new 
cyclotron designs.   Fraser and colleagues at Chalk 
River Nuclear Laboratories were the first to realize that 
for operations above 3T, there could be a simultaneous 
improvement in magnetic field accuracy due to the 
likelihood of full saturation of the iron poles, while 
significantly reducing size and overall cost for a given 
energy [39]. Cyclotrons have a unique scaling of the 
final energy (T), radius (r) and field (B), for a given ion 
of charge Q = Ze and mass Am0: 
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Eq. (2.13) shows that for a given final energy and ion, 
increasing the field results in a decrease in the size of 
the cyclotron, and this scaling holds for all 3 cyclotron 
types.  A significant argument for the development of 
the superconducting cyclotron proposed by Blosser and 
Johnson was to construct a compact hadron therapy 
cyclotron suitable for hospital use [40].  In the 1980s, 
superconducting magnets were used to exploit this 
scaling law to realize compact heavy ion isochronous 
cyclotrons at fields around 5T [41].  The first 
superconducting cyclotron, a K500 heavy ion 
accelerator shown schematically in Fig. 18, was 
successfully fabricated at Michigan State University 
(MSU).  This accelerator is still in service for research 
today as an injector for a larger K1200 cyclotron built at 
MSU.  
      A total of 9 superconducting isochronous cyclotrons 
operating at fields in the range of 3-5T were built for 
heavy ion nuclear science from 1981 through 1992.  All 
of these machines are still operating, and are almost an 
order of magnitude more compact than equivalent 
energy conventional resistive magnet cyclotrons.  Since 
cyclotron sub-systems and facility overall size scale 
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with the cyclotron size, this effect also had a dramatic 
effect 
 
Fig. 18.  The MSU K500 cyclotron is a 3 sector, spiral hill 
superconducting isochronous cyclotron. It has a peak field of 5.5T. It 
is a variable energy heavy ion accelerator and was the first operating 
accelerator of any kind to employ a superconducting magnet.  
 
on the overall facility costs. Further, since the magnets 
are superconducting and the RF systems are now more 
compact, overall power and cooling requirements are 
again significantly decreased.   
      In the 1980s, studies of cyclotrons with fields 
beyond 5T were made, but the magnet technology was 
viewed as limiting, as was the engineering complexity 
of higher field isochronous machines. One of the major 
difficulties with the very high-field magnets was the 
strength of the materials required to stably contain the 
coils and related structure. Successful studies were 
performed for a superconducting synchrocyclotron [42] 
and for an 8T cyclotron magnet [43]. However, through 
the late 1990s, resistive cyclotron magnet designs 
remained at 1-3T field levels and superconducting 
magnet designs remained around 3-5 T.       
      While dedicated medical cyclotrons are discussed in  
t 
 
Fig. 19.  The 50 MeV Harper Grace Deuteron cyclotron for neutron 
beam radiotherapy.  The 4.6 m O.D. gantry rings allowed this 
cyclotron to rotate +/- 180 degrees around the reclining patient with 
the liquid helium cooled magnet fully energized but the beam stopped 
during rotation  
 
detail in Section 3 below, we note one unique 
superconducting cyclotron designed and fabricated at 
MSU for clinical medical use here. Studies were 
initiated at MSU in 1984 for a 50 MeV compact 
superconducting deuteron cyclotron for Neutron Beam 
Radiotherapy [44]. This cyclotron, shown in Fig. 19, 
was mounted on a pair of gantry rings in an available 
spectrometer pit at MSU National Superconducting 
Cyclotron Laboratory (NSCL) for testing and had an 
internal beryllium target that yielded a neutron spectrum 
peak at 25 MeV with an order of magnitude more 
neutrons per deuteron than a same energy proton beam 
[45].  It was built jointly by NSCL and the MedCyc 
Corporation, commissioned at NSCL in April 1989, and 
installed the next year at Harper Grace Hospital in 
Detroit, Michigan [46]. Neutron radiotherapy never 
caught on as a mainstream oncology technique, but this 
machine was in clinical operation until 2008, when the 
neutron radiotherapy program at Harper Grace was 
discontinued. 
 
3. Commercial Medical Cyclotrons 
 
 The original cyclotron concept, invented by Lawrence 
in 1931, has been developed over the last 8 decades into 
machines that can provide any ion and energy desired 
for research or applications given the practical limit of 
cost. The applications of cyclotron beams in medicine 
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and industry have grown from the first investigations of 
John Lawrence in the 1930s to the point where 
commercial cyclotrons are designed and built to 
specifications to meet a large array of user applications, 
including industry, national security and medicine. 
      In general, most of the commercially available 
isotope production machines are room temperature 
sector-focused cyclotrons employing either radial (< 30 
MeV) or spiral ridge sector magnets. The hadron 
therapy facilities in operation today use a variety of 
decommissioned high-energy research accelerators 
(IUCF for example), a few specially built accelerators, 
and an ever-growing assortment of commercially 
available treatment facilities. Indeed manufacturers are 
now marketing complete isotope production and hadron 
therapy facilities to hospitals around the world. In this 
section, an attempt will be made to highlight some of 
the medical applications and the commercial 
manufactures of the medical cyclotrons. Given the large 
and increasing number of these machines operating 
today around the world, the authors will undoubtedly 
miss some of these.  
 
3.1. Medical Isotope Production 
 
Phillips introduced the first commercial cyclotron for 
medical isotope production in 1966 [47].  This 28 MeV 
proton cyclotron demonstrated that cyclotrons could be 
a cost effective source of medical isotopes. Cyclotrons 
have been the main accelerator source of medical 
isotopes ever since, with hundreds of units deployed by 
many companies.  The Philips cyclotron produced 15 
MeV deuteron and 38 MeV 3He beams.  Prior to the 
commercial isotope production cyclotron, most 
radioisotopes were produce in research nuclear reactor.  
      Cyclotron produced medical isotopes are used in 
planar (2D) imaging studies with the gamma camera, 
and computed tomography (3D) such as Single Photon 
Emission Computed Tomography (SPECT), Positron 
Emission Tomography (PET), and PET/CT.  Generally 
a compound labeled with a radioactive tracer, prepared 
in a modular chemistry unit from an irradiated target 
material, is introduced in vivo. The tracer element, a 
gamma ray emitter, travels through the body and 
collects in specific parts of the body depending upon the 
chemistry of the compound, which can then be imaged 
for clinical diagnostic purposes or treatment. For 
instance, Iodine collects in the thyroid glands and 
tumors. In the simplest case, Planar Imaging, single 
emitted gamma rays are imaged with a gamma camera, 
showing a 2D distribution of the tracer radioisotope at 
active sites in the body.   SPECT is similar to planar 
imaging in that multiple 2D images are obtained by 
rotating the gamma camera around the patient and then 
a 3D image is computer generated.  The primary SPECT 
isotopes used for medical imaging produced by 
cyclotrons are: 99mTc for bone, myocardial and brain 
scans; 123I for tumor scans and 111In for white blood 
cells. 
      PET differs from SPECT in that the tracer elements 
are short lived positron emitters, i.e., 11C, 13N, 15O, and 
18F, which are used to study brain physiology and 
pathology [8].  Positrons readily annihilate with any 
free electron in the body yielding a pair of 511 keV 
photons. The two 511 keV photons are emitted at nearly 
180 degrees from each other. Timing can be used to 
determine the location of the positron annihilation event 
and thus 3D images can be constructed with computer 
analysis.  The timing also improves the signal-to-noise 
ratio and fewer events are needed to construct the 
image. PET/CT and PET/MRI are used to co-registered 
anatomic and metabolic information simultaneously 
from PET and CT or MRI data. The main PET tracer is 
FDG, a glucose analog molecule labeled with Flourine-
18 and produced typically in an 18 MeV proton 
cyclotron.   
      A representative (i.e., very incomplete) list of the 
manufacturers of medical isotope production cyclotrons 
is provided in Table 1, which illustrates the variety of 
beams and energies available to the medical community 
for isotope production [48]. One of the earliest 
commercial cyclotrons was the CS-15 H+/D+ machine 
marketed by the Cyclotron Corporation in Berkeley, 
California. Several of the accelerators listed were 
designed and manufactured by a single firm. The TR-30 
and CS-30, for example, was designed originally by the 
accelerator group at TRIUMF but was then marketed 
and sold under the names listed by the companies listed 
in Table I. From this list, it is obvious that in the years 
after 1975, the sale and use of these isotope production 
machines grew at a very rapid pace.   
      The majority of medical isotope production 
cyclotrons accelerate H- ions.  The reason for this is that 
a simple beam extraction process is used.  Some of the 
H- ions impinging on a thin internal target, called a 
“stripper foil,” set at an internal radius and have their 2 
electrons removed (“stripped” away) and the resulting 
H+ ions follow a reverse curvature orbit (with respect to 
the H- ions) and are directed out of the cyclotron. The 
remaining un-stripped ions continue to accelerate to a 
larger radius where they can be stripped at a higher 
energy.  Multiple thin “stripper foils” can be inserted at 
several radii within the cyclotron, making it possible to 
simultaneously extract several H+ beams of different 
energies from a single cyclotron. H- Cyclotrons operate 
at magnetic fields of 1T or less to avoid Lorentz 
stripping, i.e., magnetic removal of the extra electron 
attached to the proton [49].  
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      The IBA Cyclone 30, introduced in 1986 and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE I 
 
Representative List of Commercial Cyclotrons Used for Isotope Production 
Manufacturer Model Particle Energy   (MeV) 
Intensity  
(µA) 
First  
Available 
TR 13 H-  13 100 1994 
TR 14/TR19 H- 14 – 19  300  
TR 24 H- 15 – 24  300  
TR 30 H- 15 – 30  1000 1990 
Advanced Cyclotron Systems 
7851 Adlerbridge Way 
Richmond, BC 
(EBCO) 
TR 30/15 H-, D- 30/15 1000 1994 
Cyclone 3 D- 3.5  100  
Cyclone 10/5 H-, D- 10/5 100 1988 
Cyclone 18+ H+ 18 2000 1994 
Cyclone 18/9 H-, D- 18/9 100 1992 
Ion Beam Applications s.a. 
Chemin du Cyclotron 3 
B-1348 Louvan-la-Neuve, 
Belgium 
Cyclone 30 H- 30  500 1986 
MC 16 H
-, D- 
3He, 4He 
17 /8.3  
12.4 /16.5  50 1990 
MC 32 NI H- , D- 16-32/8.5-16  60 1990 
MC 35 H
-, D-
3He, 4He 
7.5-35/3.8-18 
5.6-47/7.5-16.5 75  
MC35, 40 H+, D+ 8-40/20 75 1979 
MC50 H+, D+ 50/25 50 1989 
Scanditronix Wellhofer. AB 
Stalgatan 14 
Uppsala, Sweden 
MC60PF H+ 60 35 1984 
MINItrace H- 9.6   1993 General Electric 
www.GEhealthcare.com PETtrace H-, D- 16.5/ 8.4   1993 
RDS Eclipse  
RDS 112 Siemens (CTI) www.Siemens.com/healthcare 
RDS 111 
H- 11.0  100 1987 
CS-15 H+, D+ 15/8  60 1967 
CS-22 H+, D+ 22/12 50 1970 
CS-28 H+, D+ 24/14 50 1974 
CS-30 H+, D+ 26/15 60 1973 
The Cyclotron Corporation* 
950 Gilman St. 
Berkeley, CA 
 
CP-42 H- 42 200 1980 
HM-18 H-, D- 18/10 70 1991 
480 AVF H+ 30 80  1985 
750 AVF H+ 70 55 1985 
Sumitomo Heavy Industries, Ltd 
2-1-1 Yato-cho 
Ranashi City, Japan 
930 AVF H+ 90 10  
BC168 H+, D+ 16/8 70 1982 
BC1710 H+, D+ 17/10 70 1981 
BC2211 H+, D+ 22/11 70 1989 
Japan Steel Works, Ltd 
Muroran, Japan 
BC3015 H+, D+ 30/15 70 1985 
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Fig. 20.  The widely deployed IBA Cyclone 30 Isotope production 
cyclotron accelerates protons from 18-30 MeV, also simultaneously 
accelerating deuterons (9-15 MeV) and features dual isotope 
production targets. 
 
shown in Fig. 20, was a big step forward. It produced 
significantly higher H- currents per unit wall plug power 
and had two independent stripper foils and isotope 
production targets [50].  Beam intensities up to 1 mA 
are now available from these accelerators. Today, 
isotope production cyclotrons are available 
commercially in energies from 5-90 MeV from EBCO, 
SHI, GE, Japan Steel Works, IBA, and Siemens 
(formerly CTI). Most of these later generation 
cyclotrons are variable energy and particle, can have 
multiple extracted beams, and come complete with built 
in target stations and computer control systems designed 
to permit operation by trained technical personnel who 
are not required to be expert accelerator designers or 
builders.  
 
3.2.  Ion Beam Therapy Cyclotrons 
 
The 1946 suggestion of Robert Wilson [12] to use high 
energy protons to kill deep seated tumors in the human 
body, became a reality beginning in the late 50s, and has 
grown into a well establish protocol for curing a host of 
otherwise untreatable cancers, as well as a preferred 
method of curing other cancers while reducing radiation 
damage side-effects. This cancer-fighting technique is 
referred to as “hadron therapy” or “ion beam therapy” 
(IBT) and is most effective in eliminating well localized 
cancerous tumors located within the human body, 
particularly in the head and neck areas. This section, 
like those above, is not intended to describe the full 
range of medical applications for IBT, but seeks to 
describe the required properties of the treatment beams 
and delivery systems, and list the present commercial 
suppliers of applicable cyclotron-based IBT facilities.            
      The basic physics that makes hadron therapy so 
attractive is the manner in which high-energy particles 
(protons, deuterons, pions, and heavier ions) lose energy 
while passing through matter, as described in Section I. 
The peak in the energy loss profile at the end of an 
energetic particle’s range, illustrated in Fig. 1, is called 
the Bragg peak. The depth of penetration of the ion 
beam into the body depends precisely upon the particle 
type and energy used for the IBT treatment, as well as 
the density of the area to be penetrated. This energy loss 
property allows the physician to precisely target a tumor 
located within the human body while sparing radiation 
damage to the healthy tissue around it. A 160 MeV 
proton beam will penetrate 15 cm into the human body. 
Successive beams of lower energies and intensities can 
be directed at the tumor so as to uniformly irradiate the 
whole depth of the tumor.  Beam apertures and Lucite 
compensators are used to map the lateral shape and 
distal (rear) edge of the tumor These devices are shown 
in Fig. 21. A contour map of the area radiated by a 
proton beam using this technique is also shown, with the 
red area being the highest concentration of radiation 
delivered to the body. The green circle represents a 
sensitive organ that should not receive damaging 
radiation, illustrating the capability of this treatment 
protocol to spare healthy tissue. These very basic 
techniques have been improved over the years with 
precise beam scanning and intensity modulation 
techniques that are used to give a precise 3-dimensional 
conformal map of the tumor with the treatment beam.  
        The majority of the existing hadron therapy 
facilities today use protons, but a few are able to use 
heavier ion beams such as helium, carbon and neon. 
IBT using pion beams has also been conducted. The ion 
beam property used to compare the radiobiological 
effectiveness of hadron treatment is its Linear Energy 
Transfer (LET) to the tumor. Ionizing radiation destroys 
the ability of cells to divide and grow by damaging their 
DNA strands. Activated radicals  
 
 
 
Fig. 21. Brass Beam Aperture and Lucite compensator used together 
with the SOBP to confine the maximum ionizing energy of a proton 
beam to a tumor. 
produced from atomic interactions is the primary cause 
of radiation damage by photons, electrons, and protons. 
These types of radiation are called low linear-energy-
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transfer (low LET) radiation. Neutrons and heavy ions 
have a high LET compared with protons and photons. 
All these ions have been used for hadron therapy in 
the past. There is much debate among clinicians about 
the relative effectiveness of the various ions species in 
curing cancerous tumor diseases, although a few very 
general facts are agreed upon by most: 
 
• Most localized cancers can be effectively treated 
with low LET protons or with photons.  
• About 10% of tumors have a high resistance to 
low LET treatment and these can often be 
successfully treated with the higher LET heavy ion 
beams such as carbon. 
• Carbon ions have better dose distributions (less 
lateral scattering and collateral damage to adjacent 
healthy tissue) than protons.  
• More study is required to accurately determine the 
most effective treatment protocols. 
 
      The facility costs are the primary reason that there 
are thousands of photon cancer treatment facilities 
today. Commercially available photon radiation 
treatment facilities, based on low energy electron linear 
accelerators, are well within the budget of most hospital 
facilities. There are currently about 30 operating IBT 
facilities in the world, of which only a few have a heavy 
ion capability. Yet, regardless of the techniques used, all 
IBT facilities require an ion beam source, and a particle 
accelerator such as a cyclotron, that can deliver a 
precise beam energy and intensity.  
 
3.2.1. Proton Therapy Treatment Facilities 
 
A 230 MeV proton beam will penetrate 32 cm into the 
human body, a depth large enough for most human 
applications; hence, this has become the canonical 
energy for all proton therapy accelerators. The early 
trials in the development of IBT by John Lawrence, the 
scientists at the GWI, Sweden and the Harvard 
synchrocyclotron facilities were discussed in Section 
2.2. This work was done with research cyclotrons or 
cyclotrons converted for medical applications at the end 
of their useful physics research life. The first hospital 
based proton therapy treatment facility in the United 
States, The John M. Slater Proton Treatment and 
Research Center, was installed at the Loma Linda 
University Medical Center in San Bernardino, 
California. The facility was the first specifically 
designed for use as a Proton Therapy Treatment 
Facility. The accelerator, a 370 MeV proton 
synchrotron, and beam delivery systems, including the 
360o rotating gantries, were designed at the Fermi 
National Accelerator Laboratory in Batavia, Illinois by 
Fred Mills and Frank Cole [51]. While this paper is not 
discussing synchrotron accelerators, this facility is 
worth mentioning here, as it was a milestone for the 
acceptance of IBT as a superior treatment protocol for 
several cancers in the United States. Several proton 
therapy facilities around the world had been operating 
for several years, particularly in Europe and Japan, but 
the primary impediment to the use of proton therapy 
was in the U.S. due to cost. 
      The second proton therapy facility to begin 
operations in the U.S. was the Northeast Proton 
Treatment Center (NPTC), a new commercially built 
IBT facility installed at the Massachusetts General 
Hospital in Boston [52]. This facility, recently renamed 
the Francis H. Burr Proton Therapy Center, replaced the 
pioneering and aging Harvard synchrocyclotron proton 
therapy facility that had been in operation in 
conjunction with the Harvard Medical School since 
1961. The new treatment facility was designed and built 
by Ion Beam Applications (IBA) in Belgium [53] (the 
same company that manufactures the “Cyclone” series 
of isotope production cyclotrons listed in Table I). The 
facility, consisting of a 230 MeV superconducting 
cyclotron, a beam delivery system and 3 treatment 
rooms (wo of which house 360o rotating gantries), is the 
first commercially built, installed and operating hadron 
therapy facility in the world.  A photo of the cyclotron, 
an IBA C235, and a layout of this treatment facility are 
shown in Figs. 22 and 23. The IBA facilities typically 
consist of 3 to 4 treatment rooms. Since the 
commissioning of this facility, IBA has installed a total 
of 13 additional facilities world wide, 60% of the total              
 
 
  
Fig. 22. An IBA Cyclone 230 superconducting cyclotron 
manufactured for IBT. Compare the size of this 230 MeV proton 
cyclotron with the 220 MeV Indiana University room temperature 
proton cyclotron shown in Fig. 17 using the men in the respective 
pictures. 
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number of commercial proton therapy facilities (30) 
installed or under construction world wide as of 2009.            
      Yet another company, Varian Medical Systems in 
Palo Alto, California, is marketing a proton therapy 
system based on an Accel 250 MeV proton 
superconducting synchrotron, shown in Fig. 24. This 
cyclotron was based on the design for a superconducting 
cyclotron by H. Blosser, the inventor of the 
superconducting cyclotron. Varian acquired Accel 
Corporation in 2007, and fabricated the machine now 
installed at PSI Switzerland that is being used for IBT 
[54].     
   
3.2.2. Heavy Ion Beam Facilities 
 
There are currently four IBT facilities around the world 
that use heavy ions (carbon) for IBT [55]. Two of these 
facilities are located in Japan, which has 7 operating 
IBT facilities. There are another 6 additional IBT 
facilities under construction in Japan, and 3 of these will 
be heavy ion facilities. An additional 3 carbon IBT 
facilities are presently under construction in Europe and 
one is under construction in China.  
      All of the existing carbon IBT facilities use a 
synchrotron accelerator to produce the energy required 
for a carbon beam to penetrate deep into the human 
body. Carbon, with 6 protons and 6 neutrons, is  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
approximately 12 times more massive than a proton, 
and thus requires significantly higher energies to 
penetrate deep into the human body than protons. For a 
charge to mass ratio (q/a) of ½, a fully stripped 320 
MeV/amu carbon beam will penetrate 15 cm into the 
body. Consequently all of the present carbon facilities 
presently use high energy synchrotrons to produce the 
required energy carbon beams for IBT.  These are 
relatively large and complex facilities compared to the 
commercial proton IBT centers.          
      IBA from Belgium, has designed a high-field (4.5 T) 
 
Fig. 23. Facility layout of the NPTC Proton Therapy Treatment center 
showing the relative locations of the cyclone 30, beam delivery 
systems and 3 treatment rooms. 
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Fig. 24.  3D schematic of the Accel superconducting 250 MeV proton 
cyclotron. Now being marketed by Varian Corporation. 
superconducting cyclotron to accelerate ions with q/a = 
½ (H2+, He, Li, B, C, Ni, O, and Ar) to 400 MeV/amu. 
This cyclotron, called the C400, is based on the IBT 
C235 design but with higher magnetic fields and a 
larger diameter (6.4 m vs. 4.7 m). The machine will be 
able to provide 265 MeV protons as well as 400 
MeV/amu heavy ions, making it an all purpose 
accelerator for IBT applications within a very small 
footprint [56] and a serious competitor to the 
synchrotron as a practical and affordable source of ions 
for hadron therapy. The first of these accelerators will 
be installed in Caen, France. A schematic of the C400 
design is shown in Fig. 25.   
 
 
 
Fig. 25. A schematic of the IBA C400 superconducting heavy ion 
cyclotron showing some dimensional characteristics.  
     
.   
3.2.3. Commercial Hadron Facilities and Vendors 
 
      There are only a few vendors of completely 
designed and operational hadron therapy facilities and 
they are listed in Table II.  Three of the vendors are the 
major, heavy industrial corporations in Japan: 
Mitsubishi, Hitachi, and Sumitomo. Of these, Sumitomo 
is the only company marketing cyclotrons for both Pet 
isotope production (see Table I) and hadron therapy. 
Three of the vendors listed market facilities based on 
superconducting cyclotrons.  
      It is risky to count the hadron facilities operating or 
under construction today since the number changes 
rapidly. Nevertheless, there are presently 30 operating 
proton therapy centers around the world, with an 
additional 14 facilities under construction or planned. 
Of the 30 existing facilities, 16 listed in Table III use  
Table II 
Commercial Hadron Therapy System Vendors 
Manufacturer Accelerator Type 
Maximum 
Energy/ 
Particle 
Ion Beam 
Applications, 
Belgium 
S.C. Cyclotron 235MeV/P 
Varian, Inc, Palo 
Alto, CA, U.S.A. S.C. Cyclotron 250 MeV/P 
Still Rivers, Inc, 
Boston, MA, 
U.S.A 
S.C. 
Synchrocyclotron 235 MeV/P 
Optivus Proton 
Therapy 
Loma Linda, CA 
Synchrotron 370 MeV/P 
Mitsubishi Heavy 
Industries, Japan Synchrotron 370 MeV/P  
Hitachi,  
Japan Synchrotron 
250 MeV 
/PP 
Sumitomo Heavy 
Industries, Japan S.C. Cyclotron 235 MeV/P 
 
cyclotrons as the high energy particle source. Of these, 
13 facilities were manufactured and installed by IBA 
(Ion Beam Applications, s.a, Belgium) using the IBA 
C235 superconducting cyclotron. A 14th facility 
marketed by Sumitomo Heavy Industries, in 
collaboration with IBA, uses the Proteus C235 cyclotron 
design. 
   
4.  Future Accelerators for Medical Applications 
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4.1. New High Field Compact Medical Cyclotrons 
 
In 2003-2004, Timothy Antaya introduced a 
superconducting synchrocyclotron design with 9T fields 
for proton beam radiotherapy [57].  The purpose of this 
effort was to use the field scaling of Eq. 2.12 to produce 
a compact cyclotron that would enable the development 
of a low-cost, single-room Proton Beam Radio-Therapy 
Treatment (PBRT) system.  To be feasible, the compact 
cyclotron would have to be gantry mounted and have a 
final proton energy of at least 250 MeV. A 
synchrocyclotron-type accelerator was chosen because: 
(a) the prior design study at 5T [43] could be used as a 
guide, (b) it was possible to demonstrate quickly how 
the beam dynamics of synchrocyclotron would scale at 
high field, (c) the intensity requirements for PBRT, 
namely a proton beam intensity of 20-40 enA, are easily 
achievable in a synchrocyclotron, (d) the anticipated 
simplicity and inherent robustness of a weak focusing- 
Table III. 
Current List of IBA Proton Treatment Facilities 
 
Facility Name Location, Country 
Northeast Proton 
Therapy Center 
(NPTC) 
Massachusetts General 
Hospital 
Boston, MA, U.S.A. 
Midwest Proton 
Radiotherapy Inst. 
(MPRI) 
Indiana University 
Bloomington, Indiana 
U.S.A. 
Univ. Florida Proton 
Therapy Center 
(UFPTCI) 
University of Florida, 
Jacksonville, FL, U.S.A. 
Procure 1 Proton 
Therapy Center Oklahoma City, OK, U.S.A. 
Procure 2 Proton 
Therapy Center 
Warrenville, IL, 
U.S.A. 
Roberts Proton 
Therapy Center 
Univ. Pennsylvania, 
Philadelphia, PA, 
U.S.A. 
Hampton Univ. 
Proton Therapy Inst. 
Hampton Univ. 
VA, U.S.A. 
The Center for Proton 
Therapy of Orsay 
Curie Institute, 
Orsay, France 
West German Proton 
Radiotherapy Center 
(WPE) 
Essen,  
Germany 
Wan Jie Proton 
Therapy Center 
(WPTC) 
Wan Jie Hospital,  
Zi-Bo 
China 
Beijing Greatwall 
International Cancer 
Center 
The Soni-Japanese 
Friendship Hospital 
Beijing, China 
The National Cancer 
Center Seoul, South Korea 
National Cancer 
Center Hospital East 
Kashiwa City 
Chiba Prefecture, 
Japan 
 
cyclotron would be ideally suited to the requirements of 
a non-specialist operated clinical PBRT system, and (e) 
this field level, while high for accelerators, was far from 
the limits of the technology for high field 
superconducting magnets.  In order to complete this 9T 
synchrocyclotron design, it was necessary to develop a 
quantitative computational beam dynamics model for 
weak focusing-phase stable cyclotrons [58].  In 
addition, it was necessary to establish feasible magnet 
and RF engineering solutions for such high field 
cyclotrons [59]. Finally, advances in cryogenic 
engineering and components allowed the engineering of 
an orientation-independent superconducting cyclotron 
magnet that is 
  
 Fig. 26.  The 9T superconducting synchrocyclotron for proton beam 
radiotherapy is shown.  This compact high field cyclotron enables 
single room treatment at a fraction of the cost of conventional 
facilities, and widespread adoption is expected. 
 
cryogen free [60]. Since the radius decreases in 
proportion to the field increase, this 9T 
synchrocyclotron is more than 50 times less massive 
than a conventional machine of the same final proton 
energy, as shown in Fig. 26, and later in Fig. 28.     
      Many of the beam dynamics and technical 
challenges solved for the introduction of the high field 
synchrocyclotron are shared in the design and 
engineering of all cyclotron types. Weak focusing 
cyclotrons favor low energy gain per turn (ΔT1), and a 
250 MeV proton machine requires about 15,000 turns 
(ΔT1~15 keV/turn), to reach the full energy. Since the 
turn spacing varies inversely with energy and f(γ)~1,  
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Fig. 27. An unfolded set of orbits near 250 MeV in a 9T 
synchrocyclotron is shown. The radial orbit separation moves 
exponentially from a few microns to millimeters in about 20 turns, and 
then is directed out of the edge of the cyclotron field as a result of a 
set of small field perturbations. 
the turn spacing at full energy is of the order of 10 
microns in this 9T synchrocyclotron.  High extraction 
efficiency is desirable for  such a patient-in-the-room 
accelerator, hence it was necessary to develop a new 
beam extraction technique, which required an 
exceptionally precise beam dynamics simulation, using 
highly accurate computed fields [62]. 
 
                          
! 
dr
dN
= r
"T
1
T
f (#)
                           (4.1)  
 Fig. 27 shows a non-linear growth of a radial oscillation 
that results in an exponential growth in turn separation 
from around 6 microns to 1 cm in 20 turns, followed by 
passive magnetic element guided ion extraction at 250 
MeV.   
 
4.2. Compact IBT Facilities 
 
While the number of Proton Therapy Treatment Centers 
is growing at a reasonable pace, they are generally 
placed in high population density areas because of their 
size and cost (approximately $100 Million for a three 
treatment room facility with Gantries). To make this 
treatment available to larger fraction of the population, 
manufacturers are designing more modest and 
innovative one or two room facilities that would be 
more affordable ($40 Million), and hence be practical 
for installation in smaller population centers. The 
development of high field superconducting cyclotrons 
or synchrocyclotrons is making this option a reality. 
Still River Systems [63] is commissioning a one room 
Proton Beam Radio-Therapy (PBRT) system, called the 
Monarch250TM, based on a gantry mounted 9T 
synchrocyclotron shown in Fig. 28 and discussed in 
Section 4.1. This 250 MeV Synchrocyclotron is much 
smaller than the IBA C235 and Accel 250 MeV 3T 
superconducting cyclotrons shown in Figs. 22 and 24, 
and is an excellent visual demonstration of the 
dimensional scaling laws with magnetic field for 
cyclotron magnets. This cyclotron is currently 
undergoing commissioning. 
      The Still River Systems single room PBRT system 
conceptual design is shown in Fig. 29. The Monarch 
synchrocyclotron is seen mounted on a 180o rotating 
gantry within the treatment room, similar to what was 
done with the 50 MeV Harper Grace deuteron cyclotron 
in 1980. Barnes Jewish Hospital in St. Louis, Missouri 
and M.D. Anderson Cancer Center in Orlando, Florida 
have made partial commitments to purchase this system, 
which is advertised to cost $20 Million for the treatment 
equipment [64]. One of the advantages of the single 
room concept is that the equipment could be installed in  
 
 
Fig. 28. A photo of the Still River Systems Monarch250TM 
superconducting synchrocyclotron. The small size of this 250 MeV 
Proton machine is evident from the size of the man working on it. 
 
anexisting space within a hospital or traditional photon 
radiation facility. 
      Accel has also made a tentative design, shown in 
Fig. 30, for a single room PBRT system based on a high 
field cyclotron mounted on a gantry, somewhat like the 
Still Rivers design [63]. Other commercial  
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Fig. 29. The conceptual design for the Still Rivers single treatment 
room PBRT system showing the Monarch250TM mounted on a gantry 
within the treatment room. 
 
 
Fig. 30. The Accel Corp. conceptual design of a single room PBRT 
system with a gantry mounted cyclotron and beam delivery system.  
 
manufacturers such as Procure and IBA are also 
studying ways to reduce the high cost of hadron 
facilities. 
      With the recent advances in cyclotron design, the 
cost of the cyclotron (~$10 Million) is not the major 
expense for a hadron therapy facility.  Larger treatment 
centers with 3 to 5 treatment rooms (most with 
Gantries) and the infrastructure to house the facility and 
shield public areas from stray radiation are the major 
cost drivers. Thus, a small single room facility has the 
potential to significantly reduce the overall cost of a 
hadron therapy treatment system.  
 
5. Conclusions 
 
The invention and development of the cyclotron over 
the last 80 years has played a major role in our ability to 
understand the nature of matter through scientific 
research and to control disease through medical 
applications. It is remarkable how this invention has 
grown from the 27 inch 3.7 MeV proton Berkeley 
classical cyclotron in 1932, to the massive variable 
energy, variable particle research machines like the 1 
GeV proton synchrocyclotron at Gatchina in the 70s and 
80, and today, into very powerful commercially 
available 250 MeV compact proton superconducting 
applications cyclotrons. The Still River Systems/MIT 
250 MeV superconducting proton synchrocyclotron is 
smaller than the 27” Berkeley cyclotron used for the 
initial isotope production and fledgling medical studies 
performed by John Lawrence in 1938.  The 
development of the cyclotron into evermore powerful 
and compact machines is continuing at a rapid pace to  
provide smaller, more powerful, more flexible, and less 
expensive isotope production and hadron therapy 
facilities for medical applications. Today, there are 
literally thousands of cyclotrons operating daily around 
the world for medical applications. More cyclotrons are 
developed, built and sold commercially than for 
scientific research, which has moved on to much higher 
energy synchrotron accelerators like the LHC for its 
studies. Who would have guessed in 1932 that the initial 
developments and studies of the Lawrence brothers 
would have such a wide spread impact on today’s 
society? 
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